| INTRODUCTION
Prompt reperfusion remains the most effective treatment to date for preservation of myocardium following acute coronary occlusion.
However, large infarctions still occur despite timely reperfusion, due to reperfusion injury. 1 Numerous treatments have been studied to reduce reperfusion injury, with little success to date. 2 Hypothermia has shown the ability to consistently reduce infarct size when administered prior to reperfusion in preclinical studies. [3] [4] [5] [6] Results from clinical trials, however, have been inconsistent. [7] [8] [9] [10] [11] One major difference between preclinical and clinical trials is the lack of achievement of an effective degree of cooling prior to reperfusion in patients, as occurred in experimental studies. 12 In the clinical trials to date, a suggestion has been made that patients that achieved a core body temperature less than 35°C prior to reperfusion showed smaller infarcts, at least in those with anterior infarction. 8 However, sample sizes were not sufficient to confirm these findings in individual clinical studies. We therefore performed a patient-level pooled analysis from six randomized trials of endovascular cooling during primary PCI for STEMI in 629 patients, to examine the relationship between temperature at reperfusion and infarct size.
2 | METHODS
| Study population
This study is a patient-level pooled analysis of six hypothermia trials using endovascular cooling in which infarct size (IS) was assessed by either cardiac magnetic resonance (cMR) or technetium (Tc)-99m sestamibi single-photon emission computed tomography (SPECT) within 1 month after reperfusion at a core laboratory. Adverse events were followed through 30 days.
| Studies and characteristics
The randomized trials included in the pooled analysis were: COOL MI Pilot, 8 in which patients presenting with anterior or inferior STEMI within 6 h of symptom onset were randomized to primary PCI and cooling to a target temperature of 33°C using an endovascular cooling catheter (Radiant Medical Inc., Redwood City, CA) versus PCI alone.
Target temperature was maintained for 3 h post PCI; COOL-MI Pivotal, 7 in which patients presenting with anterior or inferior STEMI within 6 h of symptom onset were randomized to primary PCI and cooling to a target temperature of 33°C using an endovascular cooling catheter (Radiant Medical Inc.) versus PCI alone. Target temperature was maintained for 3 h post PCI; COOL MI II, in which patients presenting with anterior STEMI within 6 h of symptom onset were randomized to primary PCI and cooling to a target temperature of 32°C using an endovascular cooling catheter (Radiant Medical Inc.) versus PCI alone. Target temperature was maintained for 3 h post PCI; ICE-IT, 9 in which patients presenting with anterior or inferior STEMI within 6 h of symptom onset were randomized to primary PCI and cooling to a target temperature of 33°C using an endovascular cooling catheter (Innercool Therapies Inc., San Diego, CA) versus PCI alone. Target temperature was maintained for 6 h post PCI; RAPID MI-ICE, 10 in which patients presenting with anterior or inferior STEMI within 6 h of symptom onset were randomized to primary PCI and cooling to a target temperature of 33°C using an endovascular cooling catheter (Innercool Therapies Inc.) and cold saline infusion versus PCI alone.
Target temperature was maintained for 3 h post PCI; and CHILL-MI, 11 in which patients presenting with anterior or inferior STEMI within 6 h of symptom onset were randomized to primary PCI and cooling to a target temperature of 33°C using an endovascular cooling catheter (Innercool Therapies Inc.) and cold saline infusion versus PCI alone.
Target temperature was maintained for 1 h post PCI.
Data was available for each individual patient included. The data analysis included the patients with available infarct size and temperature at PCI for cooled patients, and excluded patients with prior-MI. In order to more precisely estimate the effect of hypothermia on infarct size, only patients that received cooling (per-protocol patients) were included. This analysis further refined the assessment of hypothermia trials by categorizing hypothermia patients using temperature at PCI (<35°C and ≥35°) for assessment of hypothermia and infarct size. 
| Statistical analyses

| RESULTS
Description of the trials is presented in Table 1 . Slightly less than half of the patients included in this analysis presented with anterior infarcts.
Of the patients in the control group, 45% had anterior infarcts, of the hypothermia <35°C group 44%, and of the hypothermia ≥35°C group, 44%. The baseline demographic and clinical characteristics for patients with both anterior and inferior infarcts are presented in Table 2 . The majority of the patient population were male, older (>65 years old), had a history of hypertension, and about half were smokers. In the hypothermia ≥35°C patients, history of diabetes was more prevalent (P = 0.03), and there was a higher proportion of current smokers (P = 0.03). The same pattern of distribution was found in anterior only and inferior only patients (data not shown). Control and Hypothermia <35°C. Among anterior patients, the relationship was even stronger. There was a marginal to significant association between group and infarct size in both unadjusted and adjusted models (P = 0.058, P = 0.030, respectively). In addition to a statistically significant relative reduction of 27% observed in (Table 3 ). Other models examined showed that additional covariates did not significantly effect relationship for infarct size and group (data not shown). Sensitivity analyses using lower temperature cutoffs for hypothermia groups (<34.5°C or <34°C) in anterior infarcts showed the same pattern of reduction of infarct size with smaller adjusted mean infarct size in the lower temperature group compared to controls (Supplemental Figure S1 ). Table 4 presents interaction analyses that examine effect modification by weight, ischemic time, door to balloon time, and pre-TIMI flow using adjusted means among patients with anterior infarcts with study as a random effect. Overall, we found no effect modification in the factors examined. There was a consistent pattern where adjusted mean of infarct size was smaller in patients reaching <35°C than in Controls or patients who had a higher temperature at time of PCI (Table 4) .
Incidence of adverse events in Control versus Hypothermia
patients for all patients is reported in Table 5 . There were no statistically significant differences between Control and Hypothermia patients for death (P = 0.46), re-infarction (P = 1.00), heart failure/ pulmonary edema (P = 0.72), ventricular tachycardia (P = 0.67), bradyarrhythmias (P = 0.92), or bleeding (P = 0.59) ( Table 5 ).
| DISCUSSION
The present study, drawn from a patient-level pooled analysis of six randomized trials of endovascular cooling during primary PCI in STEMI, showed a significant reduction in infarct size in patients with anterior STEMI who were cooled to <35°C at the time of reperfusion. After controlling for variability between studies, there was a clinically and statistically significant absolute reduction of 6.5%, or a 30% relative reduction in infarct size compared to Controls. The relationship between hypothermia group and infarct size was not modified by weight status, ischemic time, door to balloon time, or pre-TIMI flow.
These variables were thought pertinent to the outcomes of the study.
The ability of endovascular catheters to achieve sufficient cooling may be affected by weight status. Ischemic time and door to balloon time, particularly with significant delays due to the cooling procedure, may affect the results. The mean difference in door to balloon time between controls and hypothermia patients was 6 min (control- The presence of collateral flow and cumulative disease burden may also influence outcomes, however, this data was not available for consideration. There was no difference in deaths, ventricular arrhythmias, or re-infarction due to stent thrombosis between hypothermia and control patients Numerous strategies to reduce reperfusion injury have been unsuccessful to date. 2, 13 Hypothermia has been shown to be an effective therapy to help prevent reperfusion injury in preclinical studies when administered prior to reperfusion, regardless of the species tested. [3] [4] [5] [6] This has led to the assessment of hypothermia in clinical trials as a means to reduce reperfusion injury in patients.
Challenges to overcome for inducing hypothermia in STEMI patients included the ability to control shivering in awake patients, 14 and developing a means to rapidly reduce core body temperature in the much larger thermal mass in patients compared to most experimental models. The clinical studies included in this pooled analysis used endovascular cooling to lower core body temperature, and all were successful in controlling shivering using a combination of oral buspirone, intravenous meperidine, and surface warming. The results of these trials were mixed, and not as successful as was found in experimental studies. In all of the clinical trials, there was no significant difference in infarct size between hypothermia patients and controls.
Post-hoc analysis of one of the early endovascular cooling trials (COOL-MI) suggested that patients with anterior STEMI who were cooled to less than 35°C prior to reperfusion showed smaller infarct size relative to controls, implying a dose response relationship. 7 Preclinical studies have also reported a dose response whereby moderate (32°C) therapeutic hypothermia showed a strong dosedependent infarct size reduction and favorable hemodynamic outcomes versus mild (35°C) hypothermia. 15 Our results support the suggestion that patients with anterior STEMI who were cooled to less than 35°C prior to reperfusion (mean temperature at PCI was 34°C)
had significantly smaller infarcts compared to controls, and to patients Hypothermia influences numerous mechanisms leading to cell protection during ischemia and reperfusion, 12 and has the unique advantage of delivery to the ischemic bed in the absence of antegrade flow, prior to reperfusion, due to conduction cooling from the blood pool to the myocardium. 3 In contrast, pharmaceutical agents can only reach the ischemic territory after reperfusion, or potentially via collateral blood flow. Preclinical studies have shown that induction of cooling after reperfusion fails to reduce infarct size. 16 There were no major safety issues with hypothermia compared to the normothermia control patients. There was no difference in deaths, ventricular arrhythmias, or re-infarction due to stent thrombosis. The pooled analysis of infarct size and clinical outcomes showed that for every 5% decrease in absolute infarct size, there is a 20% reduction in risk of hospitalization for heart failure or mortality. 17 The results in this study reinforce the value of achieving sufficient cooling prior to reperfusion, and support efforts to improve the technology to cool faster and more effectively. To this end, the recently reported COOL AMI EU pilot study, which used a more powerful cooling system in patients with anterior STEMI, showed an absolute 7% (relative 30%) decrease in infarct size in the per protocol population, warranting the value in performing a fully powered randomized control trial to confirm this signal. , concluded that infarct size measured by cMR or SPECT within 1 month after primary PCI is strongly associated with all-cause mortality and hospitalization for heart failure within 1 year. 17 In this pooled analysis, however, a significant reduction of infarct size in patients cooled to <35°C persisted in spite of variability in the imaging methodology.
The results were most positive in the anterior STEMI population.
Anterior infarcts are larger, and likely provide greater accuracy for detecting changes due to treatment when measured by imaging methodology such as SPECT or cMR. 21 Further, patients presenting with anterior infarction carry the highest mortality risk, risk for heart failure post infarction, and are in the greatest need for timely reperfusion and adjunctive cardioprotection against reperfusion injury. 22 Overall, the results support the need for larger RCTs in patients with anterior STEMI using more powerful cooling devices to optimize the ability of hypothermia to reduce infarct size.
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